Navigation Links
Cord Blood America Announces 2008 Financial Results
Date:4/16/2009

tem cells offer a powerful and potentially life-saving resource for treating a growing number of ailments, including cancer, leukemia, blood, and immune disorders. To find out more about Cord Blood America, Inc. (OTC Bulletin Board: CBAI), visit our website at www.corcell.com. For investor information, visit www.cordblood-america.com.

Forward-Looking Statements

Some statements made in this press release are forward-looking statements, which are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. We use words such as "anticipate," "believe," "expect," "future," "intend," "plan," and similar expressions to identify forward-looking statements. These statements including those related to the growth of the industry, new stem cell treatments, and the Company's performance, are only predictions and are subject to certain risks, uncertainties and assumptions. Additional risks are identified and described in the Company's public filings with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation to update any forward-looking statements to reflect occurrences, developments, events, or circumstances after the date of such statement.

    CONTACT:
    Paul Knopick
    E & E Communications
    949/707-5365
    pknopick@eandecommunications.com


'/>"/>
SOURCE Cord Blood America, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
2. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
3. New Licence for Cubicin(R) (daptomycin), the First in a Novel Class of Antibiotic, is Announced Today for the Treatment of Serious Bloodstream and Heart Infections Caused by the Most Problematic UK Organisms, Including MRSA
4. The International Diabetes Federation (IDF) Recommends Tighter Control of Blood Glucose Levels After Meals in People With Diabetes
5. CDC Awards NATT Funding to Improve Blood Clot Awareness
6. FDA Clears OmniWave(TM) Endovascular System for Clot Removal in Peripheral Blood Vessels
7. Cellestis Receives FDA Approval for Blood Test for Detecting Tuberculosis
8. Blood Donations in U.S. Testing Positive for Chagas Disease
9. One of Nations Oldest Blood Services Providers Turns to Sysmex America
10. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
11. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2015)... Global Stem Cells Group ... the company’s first cellular and regenerative medicine symposium in ... day, hands-on stem cell training class Oct. 10. The ... M.D., President of Therapeutic Confrontations (CONFTERA) in Barcelona. ... in regenerative medicine and recent advances in cellular therapies, ...
(Date:5/26/2015)... 2015  A simple blood test developed at the ... early Alzheimer,s disease is a step closer to being ... guidelines that are needed before a blood test could ... Alzheimer,s & Dementia . The guidelines establish protocols and ... that includes UNT Health Science Center. "If ...
(Date:5/26/2015)... LOS ANGELES , 26. mája 2015 /PRNewswire/ ... ďakuje v mene svojej rodiny prezidentom Barackovi Obamovi ... vyjadrenú v súvislosti so stratou Dr. Rongxiang ... - http://photos.prnewswire.com/prnh/20150522/218111 Dr. Xu ... svojej dobe a jeho odhodlanie v oblasti vedy ...
(Date:5/26/2015)... Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... for the company,s Phase IIb trial of ORMD-0801, its ... Administration (FDA). The submission was made under the company,s ... Phase IIb study of ORMD-0801 for type 2 diabetics ...
Breaking Biology Technology:Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 2Stem Cell Training, Inc. Announces First European Symposium on Cellular and Regenerative Medicine 3Guidelines bring UNT Health Science Center's blood test for Alzheimer's one step closer 2Dr. Rongxiang Xu, O legende 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 2Oramed Submits Protocol to U.S. FDA for Its Phase IIb Oral Insulin Study 3
... BOZEN, Italy, December 29 Health Robotics ... agreement with the Devon International Group,(DIG), whereby ... Health Robotics,CytoCare(TM) and i.v.STATION(TM) robots in the ... unique benefits with great appeal to,Government and ...
... 29 AlloSource, one of the nation,s largest non-profit ... use in surgical procedures, will this year sponsor one ... Life float in the January 1 Tournament of Roses ... a tribute to the millions of people touched by ...
... Prescription Product Increases Length, Thickness and Darkness of EyelashesIRVINE, ... AGN ) today announced the U.S. Food and Drug ... as a novel treatment for hypotrichosis of the eyelashes. ... or not enough eyelashes. LATISSE(TM) is the first ...
Cached Biology Technology:Health Robotics Announces Partnership in the People's Republic of China With The Devon International Group 2Health Robotics Announces Partnership in the People's Republic of China With The Devon International Group 3Health Robotics Announces Partnership in the People's Republic of China With The Devon International Group 4AlloSource, Tissue Recipient Join 'Stars of Life' Affected by Organ and Tissue Donation Aboard Donate Life Float in 2009 Rose Parade(R) 2AlloSource, Tissue Recipient Join 'Stars of Life' Affected by Organ and Tissue Donation Aboard Donate Life Float in 2009 Rose Parade(R) 3Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 2Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 3Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 4Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 5Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 6Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 7Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 8Video: Allergan Announces U.S. Food and Drug Administration (FDA) Approval of Latisse(TM) -- First and Only Treatment Approved by the FDA for Hypotrichosis of Eyelashes 9
(Date:5/11/2015)... DAYTON, Ohio , May 11, 2015  Through a ... Ohio had a strong showing at AUVSI,s ... . These representatives of Ohio,s UAS ... domestic and abroad from all points along the UAS ecosystem. ... Dayton Development Coalition,s (DDC) Vice President for Aerospace Rich ...
(Date:5/6/2015)... 2015 LifeBEAM, a developer of bio-sensing technology, ... today that they will expand their partnership in bio-sensing ... cycling helmet and the first joint project between the ... in order to give cyclists more style choices and ... and Lazer announced their plan to release a new ...
(Date:4/21/2015)... , April 21, 2015 ... government policies are boosting access control systems market in ... According to a recently published report by TechSci Research ... ", the access control systems market in ... billion by 2020.The access control systems market in the ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 2LifeBEAM and Lazer Announce Expanded Partnership in Bio-Sensing Sports Gear 3Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 2Saudi Arabia Access Control Systems Market to Touch USD1.2 Billion by 2020 Says TechSci Research 3
... crystal ball. A new approach to predict whether a ... dose is best could get antibiotics to market faster ... In recent years, scientists worldwide have sounded the alarm: ... Bacteria are increasingly adept at outwitting the traditional antibiotic ...
... variation that may increase susceptibility to osteoporosis, a new study ... Louis demonstrated that in women the variant gene speeds up ... in the bones of the hip. , The study will ... Bone and Mineral Research and is available online. , ...
... been found by Health Canada and the U.S. Food ... or bottled foods. A new study by McGill researchers ... explains the presence of this chemical in a wide ... the October, 2004 issue of Journal of Agricultural and ...
Cached Biology News:New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 2New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 3New Drugs For Bad Bugs: UF Approach Could Bolster Antibiotic Arsenal 4Increased risk of osteoporosis associated with gene that one in five people have 2
Goat polyclonal to Sarcosine Oxidase ( Abpromise for all tested applications). Antigen: Microbial Sarcosine Oxidase. Entrez Gene ID: 51268 Swiss Protein ID: Q6IAJ9...
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750...
Rabbit polyclonal to XPC ( Abpromise for all tested applications). Antigen: Synthetic peptide from N-terminus of Human XPC conjugated to a carrier protein Entrez Gene ID: 7508 Swiss ...
Chicken polyclonal to HADHSC - Azide free ( Abpromise for all tested applications). Antigen: Amino acids 57-314 of HADHSC Entrez GeneID: 3033 Swiss Protein ID: Q16836...
Biology Products: